There is no goods in the shopping cart !
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 0-9
Your Position: Home > TrkB


TrkB Molecule Information

Name:Neurotrophic tyrosine kinase receptor type 2
Target Synonym:GP145-TrkB?BDNF/NT-3 growth factors receptor?Neurotrophic tyrosine kinase receptor type 2?Tropomyosin-related kinase B?Trk-B?TRKB?TrkB tyrosine kinase?NTRK2
Number of Launched Drugs:2
Number of Drugs in Clinical Trials:8
Lastest Research Phase:Approved

TrkB Protein Product ListCompare or Buy

Cat. No. Species Product Description Structure Purity Feature
NT2-H5228 Human Human TrkB / NTRK2 Protein
NT2-H5254 Human Human TrkB / NTRK2 Protein, Fc Tag

TrkB Molecule Synonym Name


TrkB Molecule Background

Neurotrophic tyrosine kinase receptor type 2 (NTRK2) is also known as BDNF/NT-3 growth factors receptor, Tropomyosin-related kinase B (TRKB) and TrkB tyrosine kinase, which belongs to the protein kinase superfamily or Tyr protein kinase family. Insulin receptor subfamily. NTRK2 / TrkB contains two Ig-like C2-type (immunoglobulin-like) domains, two LRR (leucine-rich) repeats, one LRRCT domain, one LRRNT domain, one protein kinase domain. NTRK2 / Trk-B is expressed in the central and peripheral nervous system. The catalytic activity of NTRK2 is ¡°ATP + a [protein]-L-tyrosine = ADP + a [protein]-L-tyrosine phosphate¡±. NTRK2 / TrkB involved in the development and the maturation of the central and the peripheral nervous systems through regulation of neuron survival, proliferation, migration, differentiation, and synapse formation and plasticity.

TrkB References

TrkB Public Drug Information

Name Research Code Research Phase Company First Brand Name First Approved Country First Indication First Approved Company First Approved Date Indications Clinical Trials
Cabozantinib S-malate XL-184; BMS-907351,BMS907351,XL184,XL 184,BMS 907351 Approved Exelixis, Ipsen, Takeda COMETRIQ fda Medullary thyroid cancer (MTC) EXELIXIS 2012-11-29 Renal cell carcinoma, Advanced renal cell carcinoma (RCC), Medullary thyroid cancer (MTC), Hepatocellular carcinoma (HCC) Details
Larotrectinib sulfate LOXO-101 sulfate; ARRY-470 (free base); LOXO-101 (free base); RDF76R62ID Approved Array BioPharma, Loxo Oncology, Bayer VITRAKVI fda Solid tumours LOXO ONCOLOGY INC 2018-11-26 Solid tumours Details

TrkB Clinical Drug Information

Name Research Code Research Phase Company Indications Clinical Trials
Ropotrectinib TPX-0005,TPX0005,TPX 0005 Phase Ⅱ Non small cell lung cancer (NSCLC), Solid tumours Details
Brain-derived neurotrophic factor Phase Ⅱ Max Planck Institute of Experimental Medicine, Sumitomo Dainippon, Amgen, Regeneron Pharmaceutical Amyotrophic lateral sclerosis (ALS) Details
BN-201 BN-201 Phase Ⅰ Bionure Optic neuritis, Neuromyelitis optica (NMO) Details
Altiratinib DCC-22701; DCC-2701; DP-5164; T678746713,DP5164,DCC2701, Phase Ⅰ Deciphera Solid tumours Details
Entrectinib NMS-E628; RXDX-101 NDA Filing Nerviano Medical Sciences, Ignyta Pharma, Roche, Chugai Neuroblastoma, Non small cell lung cancer (NSCLC), Solid tumours, Colorectal cancer, Acute myeloid Leukemia (AML) Details
CE-245677 CE-245677 Phase Ⅰ Pfizer Cancer Details
DS-6051 DS-6051; DS-6051a; DS-6051b,DS6051,DS6051a,DS6051b Phase Ⅰ Daiichi Sankyo, AnHeart Therapeutics Solid tumours Details
PLX-7486 PLX-7486; PLX7486-TsOH Phase Ⅲ Daiichi Sankyo Pancreatic cancer Details

This web search service is supported by Google Inc.